tradingkey.logo

Simulations Plus Inc

SLP

15.860USD

+0.430+2.79%
Close 09/18, 16:00ETQuotes delayed by 15 min
319.04MMarket Cap
LossP/E TTM

Simulations Plus Inc

15.860

+0.430+2.79%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
17 / 207
Overall Ranking
77 / 4721
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 6 analysts
Buy
Current Rating
25.333
Target Price
+64.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 29.88% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 70.01M.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 48.18%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 48.18%.
Undervalued
The company’s latest PE is -5.04, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 20.10M shares, decreasing 10.63% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.17M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.61.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 9.11, which is higher than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 20.36M, representing a year-over-year increase of 9.81%, while its net profit experienced a year-over-year increase of 2245.90%.

Score

Industry at a Glance

Previous score
9.11
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

7.55

Operational Efficiency

9.33

Growth Potential

9.21

Shareholder Returns

9.45

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -4.90, which is -1796.20% below the recent high of 83.14 and 1560.34% above the recent low of 71.58.

Score

Industry at a Glance

Previous score
1.20
Change
1.6

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 17/207
No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.33, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Simulations Plus Inc is 25.00, with a high of 31.00 and a low of 20.00.

Score

Industry at a Glance

Previous score
8.33
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts
Buy
Current Rating
25.333
Target Price
+64.18%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

94
Total
4
Median
7
Average
Company name
Ratings
Analysts
Simulations Plus Inc
SLP
6
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
34
Veeva Systems Inc
VEEV
32
Thermo Fisher Scientific Inc
TMO
31
1
2
3
...
19

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 8.53, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 16.71 and the support level at 13.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
8.53
Change
0.24

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(1)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.446
Buy
RSI(14)
64.340
Neutral
STOCH(KDJ)(9,3,3)
83.194
Overbought
ATR(14)
0.659
High Vlolatility
CCI(14)
165.268
Buy
Williams %R
13.712
Overbought
TRIX(12,20)
0.239
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
15.290
Buy
MA10
14.686
Buy
MA20
14.442
Buy
MA50
14.090
Buy
MA100
20.106
Sell
MA200
25.131
Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 99.87%, representing a quarter-over-quarter decrease of 3.46%. The largest institutional shareholder is The Vanguard, holding a total of 1.17M shares, representing 5.82% of shares outstanding, with 2.32% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Woltosz (Walter S)
3.32M
-0.60%
BlackRock Institutional Trust Company, N.A.
2.29M
-1.07%
Conestoga Capital Advisors, LLC
2.61M
+17.21%
The Vanguard Group, Inc.
Star Investors
1.10M
-4.18%
Janus Henderson Investors
896.34K
+65.10%
State Street Global Advisors (US)
706.51K
-2.01%
Columbia Threadneedle Investments (UK)
422.80K
+7.20%
Dimensional Fund Advisors, L.P.
475.53K
+13.43%
Geode Capital Management, L.L.C.
385.85K
-3.69%
1
2

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.12, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.12
Change
0
Beta vs S&P 500 index
1.00
VaR
+4.22%
240-Day Maximum Drawdown
+66.33%
240-Day Volatility
+61.39%
Return
Best Daily Return
60 days
+7.82%
120 days
+26.85%
5 years
+26.85%
Worst Daily Return
60 days
-25.76%
120 days
-25.76%
5 years
-25.76%
Sharpe Ratio
60 days
-0.07
120 days
-0.60
5 years
-0.27
Risk Assessment
Maximum Drawdown
240 days
+66.33%
3 years
+75.81%
5 years
+86.08%
Return-to-Drawdown Ratio
240 days
-0.73
3 years
-0.27
5 years
-0.17
Skewness
240 days
-0.91
3 years
-0.42
5 years
-0.49
Volatility
Realised Volatility
240 days
+61.39%
5 years
+50.38%
Standardised True Range
240 days
+8.13%
5 years
+11.37%
Downside Risk-Adjusted Return
120 days
-65.80%
240 days
-65.80%
Maximum Daily Upside Volatility
60 days
+45.06%
Maximum Daily Downside Volatility
60 days
+54.01%
Liquidity
Average Turnover Rate
60 days
+3.34%
120 days
+2.51%
5 years
--
Turnover Deviation
20 days
+61.08%
60 days
+181.11%
120 days
+111.29%

Peer Comparison

Healthcare Equipment & Supplies
Simulations Plus Inc
Simulations Plus Inc
SLP
7.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
8.20 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.19 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
8.09 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
7.94 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
7.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI